From what 9 stock analysts predict, the share price for ImmunoGen Inc (IMGN) might decrease by 0.45% in the next year. This is based on a 12-month average estimation for IMGN. Price targets go from $31.00 to $31.26. The majority of stock analysts believe IMGN is a hold. Please note analyst price targets are not guaranteed and could be missed completely.
ImmunoGen Inc has a total of 9 Wall St Analyst ratings. There are 0 buy ratings, 9 ratings, and 0 sell ratings. Since most analysts have a hold consensus rating, the expectation is that ImmunoGen Inc will generate similar returns as the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
boris peaker TD Cowen | Buy | None | maintained | Nov 2, 2023 |
brian cheng J.P. Morgan | Buy | $22.0 | upgraded | Sep 13, 2023 |
matt phipps William Blair | Buy | None | maintained | Jun 11, 2021 |
john scott Cowen & Co. | Buy | None | reiterated | Dec 4, 2020 |
debjit chattopadhyay Guggenheim | Buy | $9.0 | reiterated | Aug 3, 2020 |
matthew eckler RBC Capital | Buy | $12.0 | upgraded | Jul 6, 2017 |
laura chico Wedbush | Buy | $12.0 | upgraded | Jul 6, 2017 |
eun yang Jefferies | Buy | $16.0 | reiterated | Mar 9, 2016 |
john sonnier William Blair | Buy | None | maintained | Jan 29, 2016 |
christopher marai Nomura | Buy | $24.0 | reiterated | Nov 10, 2015 |
adnan butt Guggenheim | Buy | $18.0 | rated | Nov 7, 2013 |
ling wang BTIG | Buy | $21.0 | initiatedcoverage | Sep 30, 2013 |
thomas wei Jefferies | Buy | $21.0 | reiterated | Sep 9, 2013 |
robert hazlett BTIG | Buy | $19.0 | initiatedcoverage | Aug 26, 2013 |
george farmer Scotiabank | Buy | $17.0 | reiterated | Jan 30, 2012 |
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.
When did it IPO
1989
Staff Count
277
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Mark Joseph Enyedy
Market Cap
$8.72B
In 2023, IMGN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IMGN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
IEP-USD
$21.54
LBRDA-USD
$61.37
LBRDK-USD
$60.87
DBX-USD
$23.86
OLED-USD
$181.76
LCID-USD
$3.7